Company Filing History:
4 out of 4,884 
4 out of 3,559 
2 out of 319 
Years Active: 1999-2023
Title: Edgardo Delfino Carosella: Innovator in HLA-G Therapeutics
Introduction
Edgardo Delfino Carosella, based in Paris, France, is a distinguished inventor renowned for his contributions to the field of immunology, particularly through his work on HLA-G molecules. With 8 patents to his name, Carosella's innovations focus on the diagnostic and therapeutic uses of HLA-G transcripts and isoforms.
Latest Patents
Among his latest patents, Carosella has developed groundbreaking technologies in the treatment and understanding of organ/tissue rejection. His patent on "HLA-G transcripts and isoforms and their uses" encompasses new RNA transcripts and proteins derived from the HLA-G gene. This disclosure includes pharmaceutical compositions, specific primers, and antibodies aimed at therapeutic applications. Furthermore, his patent titled "Multimeric polypeptides of HLA-G including at least two alpha3 domains and pharmaceutical uses thereof" introduces multimers of alpha3 peptides of the HLA-G antigen, along with their methodologies and pharmaceutical applications for treating various diseases, particularly related to organ transplantation.
Career Highlights
Edgardo Carosella has made significant strides in his career, holding positions at prestigious organizations such as the Commissariat à l'Énergie Atomique et aux Énergies Alternatives. Through these roles, he has been at the forefront of research and development in molecular biology, specifically targeting HLA-G related applications.
Collaborations
Throughout his professional journey, Carosella has collaborated with esteemed colleagues, including Philippe Moreau and Marek Kirszenbaum. These collaborations have fostered a rich environment for innovation, resulting in patents that significantly advance our understanding and treatment of disease.
Conclusion
Edgardo Delfino Carosella stands out as a crucial innovator in the realm of HLA-G therapeutic applications. His continued research and dedication to technology development not only enhance medical science but also pave the way for future advancements in immunotherapy. His patents continue to influence the field, offering hope for improved therapeutic strategies in the treatment of organ rejection and other related ailments.